External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Aurobindo Pharma' reported PAT missed estimates by 5%. Consol. Revenue grew by 11.4% YoY, Gross margins decreased by 183 bps YoY and EBITDA margins decreased by 130 bps YoY.</li><li>US revenue USD$ 370 Mn, +2% YoY, however injectable business in the US reported flat growth YoY despite good numbers of injectable approvals in last year.</li><li>Oral and OTC business has driven growth in the US by 6% and 17% YoY respectively.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Aurobindo Pharma' reported PAT missed estimates by 5%. Consol. Revenue grew by 11.4% YoY, Gross margins decreased by 183 bps YoY and EBITDA margins decreased by 130 bps YoY.US revenue USD$ 370 Mn, +2% YoY, however injectable business in the US reported flat growth YoY despite good numbers of injectable approvals in last year.Oral and OTC business has driven growth in the US by 6% and 17% YoY respectively.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma Ltd - Number of Livers to Drive Topline